1. Adams JL, Greener BN, Kashuba AD. Pharmacology of HIV integrase inhibitors. Curr Opin HIV AIDS. 2012;7(5):390–400.
2. Dejesus E, Cohen C, Elion R, et al. First report of raltegravir (RAL, MK-0518) use after virologic rebound on elvitegravir (EVT, GS 9137) (abstract no. TUPEB032 plus poster). In: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 22–25 Jul 2007, Sydney.
3. Hazuda DJ, Miller MD, Nguyen BY, et al. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a phase 2 study in patients with triple-class resistant HIV-1 infection (abstract no. 8). In: 16th International HIV Drug Resistance Workshop, 12–16 Jun 2007, Barbados.
4. McColl DJ, Fransen S, Gupta S, et al. Resistance and cross-resistance to first generation integrase inhibitors: insights from a phase 2 study of elvitegravir (GS-9137) (abstract no. 9). In: 16th International HIV Drug Resistance Workshop, 12–16 Jun 2007, Barbados.
5. Garrido C, Villacian J, Zahonero N, et al. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother. 2012;56(6):2873–8.